Journal
PLOS ONE
Volume 12, Issue 11, Pages -Publisher
PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0186884
Keywords
-
Categories
Funding
- Fonds Voor Wetenschappelijk Onderzoek (FWO [1288714N, G.0601.07]
- Agentschap voor Innovate door Wetenschap en Technologie (IWT) [SB-101230, SB-121396, SB121393]
- IWT-SBO-HEPSTEM
- IWTSBO-HILI M-3D
- University of Leuven [IWT/OZM/090838]
- Federal Science Policy Office (BELSPO)-IUAP-DEVREPAIR
- Institute Aragones de Ciencias de la Salud (IACS) [BPAMER3/08/04]
- Government of Aragon [FM1048/08]
Ask authors/readers for more resources
Currently, drug metabolization and toxicity studies rely on the use of primary human hepatocytes and hepatoma cell lines, which both have conceivable limitations. Human pluripotent stem cell (hPSC) derived hepatocyte-like cells (HLCs) are an alternative and valuable source of hepatocytes that can overcome these limitations. EZH2 (enhancer of zeste homolog 2), a transcriptional repressor of the polycomb repressive complex 2 (PRC2), may play an important role in hepatocyte development, but its role during in vitro hPSC-HLC differentiation has not yet been assessed. We here demonstrate dynamic regulation of EZH2 during hepatic differentiation of hPSC. To enhance EZH2 expression, we inducibly overexpressed EZH2 between dO and d8, demonstrating a significant improvement in definitive endoderm formation, and improved generation of HLCs. Despite induction of EZH2 overexpression until d8, EZH2 transcript and protein levels decreased from d4 onwards, which might be caused by expression of microRNAs predicted to inhibit EZH2 expression. In conclusion, our studies demonstrate that EZH2 plays a role in endoderm formation and hepatocyte differentiation, but its expression is tightly post-transcriptionally regulated during this process.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available